A Phase 1b/2 Study to Evaluate the Safety, Tolerability,
Pharmacokinetics, and Pharmacodynamics of GS-5829 as a Single
Agent and In Combination with Enzalutamide in Subjects with
Metastatic Castrate-Resistant Prostate Cancer

Principal Investigator

Joshi Alumkal

Study Purpose

The purpose of this study is to study the effects of the investigational drug GS-5829 alone and in combination with the standard of care prostate cancer treatment enzalutamide on metastatic castrate resistant prostate cancer (advanced stage prostate cancer).

Medical Condition(s)

Metastatic castration-resistant prostate cancer

Eligibility Criteria

Prostate cancer that has spread to other parts of your body (metastatic)
Castration-resistant (your cancer has stopped responding to hormonal therapy)
You are in generally good health aside from your cancer

Age Range

18 - 100

Healthy Volunteers Needed


Duration of Participation

You will receive the study drug(s) for as long as your cancer does not worsen, you do not experience unacceptable side effects, and you do not withdraw your consent or decide you no longer wish to participate. After you stop taking the study drug(s) you will be followed via phone call every 3 months to see how you are doing until the study is ended.

Minors Included



Knight Clinical Trials Information Line
Phone 503-494-1080 or


Gilead Sciences, Inc.

Recruitment End


Compensation Provided


Go Back